Curatis: Strong 2024 results

Monday, April 7, 2025 @ 12:00 am

Curatis reported strong 2024 results, indicating ample cash to sustain its operations. It increased the target population 20-fold for its lead project C-PTBE-01. Curatis can apply for a BLA for C-PTBE-01, extending exclusivity in the US by 5 more years to up to 12 years, triggering the target population expansion.

Key catalysts include:

1. C-PTBE-01 - Scientific advice meeting FDA (Q2 2025)
2. C-PTBE-01 - Partnering before phase III (2025/2026)
3. C-PTBE-01 - Start phase III trials (2026)

Curatis Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Oculis: Enrollment for two Diabetic Macular Edema Phase 3 trials completed

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to follow
April 10, 2025

LimmaTech and Valneva: First shigellosis vaccination in Phase 2 infant study

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life- threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bio
April 9, 2025

New Chief Commercial Officer for Cytosurge

Cytosurge appoints Dr. Magid Haddouchi as Chief Commercial Officer to drive global expansion. With over 15 years of experience, he joins as the company engages in key 2025 events, including AACR (USA), SPMConnect (USA), and ISSCR (Hong Kong). Dr. Haddouchi will focus on expanding the reach of FluidFM technology in single-cell research and precision genome editing, enhancing customer engagement, an
April 9, 2025

Pharvaris: 4th quarter and full year 2024 financial results

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Orphan medicinal product designation granted to deucrictibant in Europe for the treatment
April 7, 2025

LubioScience expands Swiss access to cell and gene therapy solutions

LubioScience expands partnership with Amsbio, a global leader in life science reagents with a strong footprint in the cell and gene therapy, stem cell biology, 3D and organoid cell culture, glycobiology and the biospecimen field.
April 3, 2025